Assertio Historical Cash Flow
| ASRT Stock | USD 0.67 0.01 1.47% |
Analysis of Assertio Therapeutics cash flow over time is an excellent tool to project Assertio Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 64.4 M or Other Non Cash Items of 11.3 M as it is a great indicator of Assertio Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Assertio Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Assertio Therapeutics is a good buy for the upcoming year.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. About Assertio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Assertio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Assertio's non-liquid assets can be easily converted into cash.
Assertio Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Assertio Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Assertio Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.At this time, Assertio Therapeutics' End Period Cash Flow is comparatively stable compared to the past year. Change In Working Capital is likely to gain to about 5.5 M in 2025, whereas Begin Period Cash Flow is likely to drop slightly above 64.4 M in 2025.
Assertio Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Assertio Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Assertio Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (21.3M) | 16.0M | 28.1M | 8.5M | (22.9M) | (21.7M) | |
| Free Cash Flow | (65.6M) | 5.5M | 78.3M | 49.0M | 26.4M | 14.5M | |
| Begin Period Cash Flow | 42.1M | 20.8M | 36.8M | 64.9M | 73.4M | 64.4M | |
| Total Cashflows From Investing Activities | 512.8M | (18.5M) | (42.7M) | 3.1M | (48.9M) | (46.5M) | |
| Other Cashflows From Financing Activities | (13.5M) | (5.4M) | (9.1M) | (25.8M) | (350K) | (332.5K) | |
| Other Non Cash Items | (22.1M) | 4.1M | 21.5M | 267.8M | 11.9M | 11.3M | |
| Capital Expenditures | 5.5M | 1.5M | 10K | 53K | 274K | 628K | |
| Total Cash From Operating Activities | (65.6M) | 5.5M | 78.6M | 49.6M | 26.4M | 16.7M | |
| Net Income | (28.1M) | (1.3M) | 109.6M | (331.9M) | (21.6M) | (22.7M) | |
| Total Cash From Financing Activities | (468.6M) | 29.0M | (7.8M) | (44.2M) | (350K) | (332.5K) | |
| End Period Cash Flow | 20.8M | 36.8M | 64.9M | 73.4M | 50.6M | 64.5M | |
| Change In Working Capital | (44.2M) | (31.3M) | (13.0M) | 140K | 5.2M | 5.5M | |
| Depreciation | 26.4M | 29.1M | 33.4M | 28.2M | 25.8M | 26.9M | |
| Change To Liabilities | (18.7M) | (28.6M) | (28.7M) | (10.2M) | (9.2M) | (8.7M) | |
| Change To Account Receivables | 19.8M | (11K) | (996K) | 48.7M | (6.5M) | (6.1M) | |
| Change To Inventory | (291K) | 4.3M | (6.6M) | (5.0M) | (9.6M) | (9.1M) | |
| Stock Based Compensation | 10.9M | 3.5M | 7.5M | 9.2M | 5.0M | 9.1M | |
| Sale Purchase Of Stock | (866K) | (418K) | (838K) | (7.9M) | (350K) | (332.5K) | |
| Investments | 512.8M | (18.5M) | (42.7M) | 3.1M | (48.9M) | (46.5M) | |
| Net Borrowings | (154.3M) | (464.3M) | (9.8M) | (750K) | (675K) | (708.8K) | |
| Change To Netincome | 178.0M | (25.3M) | 8.8M | (51.7M) | (59.5M) | (56.5M) | |
| Change To Operating Activities | 20.7M | (26.2M) | (7.4M) | 4.8M | 4.3M | 4.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.